

# **Therapeutic Drug Monitoring**

## **Technologies, Companies & Markets**

**By**

**Prof. K. K. Jain  
MD, FRACS, FFPM  
Jain PharmaBiotech  
Basel, Switzerland**

**November 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

His important books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2017), "Drug-induced Neurological Disorders", 3<sup>rd</sup> ed (Hogrefe 2012), "Applications of Biotechnology in Cardiovascular Disorders" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

**November 2018**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:**       **+4161-6924461**  
**Email:**           **info@pharmabiotech.ch**  
**Web site:**       **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>10</b>
<b>1. Introduction .....</b>	<b>12</b>
<b>Definitions .....</b>	<b>12</b>
<b>Historical Landmarks in the development of TDM .....</b>	<b>12</b>
<b>Pharmacology relevant to TDM .....</b>	<b>13</b>
Pharmacokinetics .....	13
Pharmacodynamics .....	14
Pharmacogenetics .....	14
Pharmacogenomics .....	14
Pharmacoproteomics .....	14
Drug receptors .....	14
Protein binding .....	15
<b>Therapeutic range of a drug.....</b>	<b>15</b>
<b>Variables that affect TDM.....</b>	<b>15</b>
<b>Indications for TDM .....</b>	<b>16</b>
<b>Multidisciplinary nature of TDM .....</b>	<b>17</b>
<b>Role of TDM in personalized medicine.....</b>	<b>18</b>
<b>2. Technologies for TDM .....</b>	<b>20</b>
<b>Introduction .....</b>	<b>20</b>
<b>Sample preparation .....</b>	<b>20</b>
<b>Proteomic technologies .....</b>	<b>20</b>
Mass spectrometry .....	20
<i>Liquid chromatography MS.....</i>	<i>20</i>
<i>Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry .....</i>	<i>21</i>
<i>Combining capillary electrophoresis with MS.....</i>	<i>21</i>
<i>Gas-liquid chromatography .....</i>	<i>21</i>
<i>Tissue imaging mass spectrometry.....</i>	<i>22</i>
<i>New trends in sample preparation .....</i>	<i>22</i>
<i>Pressure Cycling Technology .....</i>	<i>22</i>
Desorption electrospray ionization imaging .....	23
High Performance Liquid Chromatography (HPLC) .....	23
<i>Ultra performance LC .....</i>	<i>23</i>
Application of HPLC and MS for separation of drug molecules .....	24
TDM using dry blood spots .....	25
<i>Analysis of dried blood spots for drugs using DESI .....</i>	<i>25</i>
<i>Quantitative analysis of drugs in dried blood spot by paper spray MS .....</i>	<i>25</i>
<b>Immunoassays .....</b>	<b>26</b>
Enzyme-linked immunosorbent assay .....	26
Cloned Enzyme Donor Immunoassay.....	26
Enzyme Multiplied Immunoassay Technique .....	27
Fluorescence Polarization Immunoassay .....	27
Particle Enhanced Turbidimetric Inhibition Immunoassay .....	27
Radioimmunometric assays .....	28
<b>Biosensors .....</b>	<b>28</b>
<b>Biochips &amp; Microarrays .....</b>	<b>29</b>
Introduction .....	29
Microchip capillary electrophoresis .....	29
Phototransistor biochip biosensor.....	30
Microchip-based fluorescence polarization immunoassay for TDM.....	30
Cellular microarrays .....	30
Microfluidics for TDM .....	30
<i>Lab-on-a-chip.....</i>	<i>31</i>
<i>Micronics' microfluidic technology.....</i>	<i>31</i>
<i>Rheonix CARD technology .....</i>	<i>31</i>
<i>Nano-interface in a microfluidic chip.....</i>	<i>32</i>
<i>Levitation of nanofluidic drops with physical forces.....</i>	<i>32</i>
Nanoarrays .....	32
<b>Nanobiotechnology .....</b>	<b>33</b>
NanoDx™.....	33
<b>Biomarkers .....</b>	<b>33</b>
Applications of biomarkers in drug safety studies .....	34
Genomic technologies for toxicology biomarkers .....	35
Proteomic technologies for toxicology biomarkers .....	35
Metabonomic technologies for toxicology biomarkers.....	35
Integration of genomic and metabonomic data to develop toxicity biomarkers.....	36

Toxicology studies based on biomarkers .....	36
<i>Biomarkers of hepatotoxicity</i> .....	37
<i>Biomarkers of nephrotoxicity</i> .....	38
<i>Cardiotoxicity</i> .....	39
<i>Neurotoxicity</i> .....	40
Biomarkers in clinical trials .....	40
<b>Molecular diagnostics</b> .....	<b>41</b>
<b>Novel technologies for TDM at point-of-care</b> .....	<b>41</b>
NanoEye .....	42
Nanobiosensors .....	43
<b>3. Drug Monitoring Instruments</b> .....	<b>44</b>
<b>Introduction</b> .....	<b>44</b>
<b>Description of important instruments</b> .....	<b>44</b>
Abbott instruments .....	44
ARCHITECT c16000 .....	44
ARCHITECT c4000 .....	45
ARCHITECT c8000 .....	45
ARCHITECT ci16200 Integrated System .....	45
ARCHITECT ci4100 Integrated System .....	46
ARCHITECT ci8200 integrated with the ARCHITECT i2000SR .....	46
ARCHITECT i1000SR .....	46
ARCHITECT i4000SR .....	47
AxSYM .....	47
Agilent's 6400 Series Triple Quadrupole LC/MS .....	48
Alfa Wassermann's ACE Alera .....	48
AMS Diagnostics' LIASYS .....	48
Beckman Coulter instruments .....	48
Beckman Coulter Unicel Series .....	48
AU5800 automated chemistry systems .....	49
AU480 .....	49
Binding Site ESP600 .....	50
bioMerieux Mini Vidas .....	50
Carolina BioLis 24i .....	50
Chromsystems' HPLC instruments .....	51
Grifols Triturus .....	51
ABX Pentra 400 .....	51
Medica EasyRA .....	52
Nova Biomedical Critical Care Xpress .....	52
Ortho Clinical Diagnostics' VITROS® family of systems .....	52
Immunodiagnostic systems .....	53
Randox instruments .....	53
Randox RX Imola .....	53
Roche instruments .....	54
Cobas® 8000 .....	54
COBAS INTEGRA® Systems .....	54
SCIEX instruments .....	54
SCIEX LC/MS/MS .....	54
Siemens instruments .....	55
ADVIA 1200 .....	55
ADVIA Centaur XP immunoassay system .....	55
CLINITEK® AUWi System .....	55
Dimension® Xpand® Plus Integrated Chemistry System .....	55
EMIT® II Plus Syva® .....	56
Viva® Drug Testing Systems .....	56
Thermo Scientific instruments .....	56
Indiko .....	56
Tosoh AIA-Series .....	57
<b>4. Applications of TDM</b> .....	<b>58</b>
<b>Introduction</b> .....	<b>58</b>
<b>Pharmaceutical research and drug development</b> .....	<b>58</b>
Clinical trials .....	58
Computerized clinical decision support systems for TDM and dosing .....	58
Medication-related interferences with measurements of catecholamines .....	59
Polymorphisms of genes affecting drug metabolism .....	59
TDM for drug safety .....	59
<b>TDM in special groups</b> .....	<b>60</b>
The aged .....	60
Children .....	60
Pregnancy .....	60

<b>TDM of prophylactic therapy .....</b>	<b>61</b>
Monitoring of vitamin D levels .....	61
Monitoring of RBC folic acid levels during pregnancy .....	61
<b>Applications according to various conditions .....</b>	<b>61</b>
Anesthesia and critical care .....	61
<i>Optimizing antimicrobial dosing for critically ill patients</i> .....	62
<i>TDM monitoring of thiopental continuous infusion in critical care</i> .....	62
<i>Role of TDM in critical care cardiac patients</i> .....	63
Cancer.....	63
Epilepsy.....	64
<i>Personalized approach to use of AEDs</i> .....	64
Infections .....	65
<i>Virus infections</i> .....	65
<i>Fungal infections</i> .....	65
Pain management .....	66
<i>Role of TDM in pain management</i> .....	66
<i>Monitoring of analgesic drugs in urine samples</i> .....	66
<i>AEDs as analgesics</i> .....	67
<i>Triptans for migraine</i> .....	67
Psychiatric disorders.....	67
<i>Guidelines for use of TDM in psychiatric patients</i> .....	67
<i>TDM of psychotropic drugs</i> .....	69
Emergency toxicology.....	69
<b>Future of TDM .....</b>	<b>70</b>
<b>5. Drugs Requiring Monitoring .....</b>	<b>72</b>
<b>Introduction .....</b>	<b>72</b>
Anticoagulants.....	73
<i>Dabigatran</i> .....	74
<b>Analgesics .....</b>	<b>74</b>
Monitoring of opioid use.....	74
<i>TDM of morphine</i> .....	75
<i>TDM of oxycodone</i> .....	75
<i>TDM of codeine</i> .....	76
<b>Antiepileptics.....</b>	<b>76</b>
Carbamazepine.....	77
<i>TDM of carbamazepine</i> .....	77
Gabapentin .....	78
Lacosamide.....	78
Lamotrigine.....	78
<i>TDM of lamotrigine</i> .....	79
Levetiracetam .....	79
<i>TDM of levetiracetam</i> .....	80
Phenobarbital .....	81
<i>TDM of phenobarbital</i> .....	81
Phenytoin .....	81
<i>TDM of phenytoin</i> .....	81
Primidone .....	82
<i>TDM of primidone</i> .....	83
Topiramate .....	83
<i>TDM of topiramate</i> .....	83
Valproic acid.....	83
<i>TDM of valproic acid</i> .....	84
TDM of multiple antiepileptic drugs in plasma/serum .....	84
<b>Antiinflammatory agents .....</b>	<b>86</b>
Infliximab .....	86
<b>Antimicrobials.....</b>	<b>86</b>
Antibiotics.....	87
<i>Amikacin</i> .....	87
<i>Anti-tuberculosis drugs</i> .....	87
<i>Chloramphenicol</i> .....	88
<i>Gentamicin</i> .....	88
<i>Tobramycin</i> .....	88
<i>Vancomycin</i> .....	89
<i>Norvancomycin</i> .....	89
Antiviral agents .....	89
<i>Anti-HIV drugs</i> .....	89
Antifungal agents.....	90
<i>Voriconazole</i> .....	90
<b>Antidepressants.....</b>	<b>90</b>
TDM of selective serotonin reuptake inhibitors .....	91

<i>Citalopram</i> .....	91
<b>Antipsychotics</b> .....	<b>92</b>
Aripiprazole.....	92
Clozapine.....	93
Quetiapine .....	93
Risperidone.....	93
TDM of AEDs in psychiatric disorders .....	94
TDM of multiple drugs in psychiatry .....	94
<b>Bronchodilators</b> .....	<b>95</b>
Theophylline.....	95
<b>Cardiovascular drugs</b> .....	<b>95</b>
Antiarrhythmic drugs.....	95
Antihypertensive drugs .....	95
<i>β-blockers</i> .....	95
Cardiotonic drugs.....	96
<i>Digoxin</i> .....	96
TDM of statins for hypercholesterolemia .....	96
<b>Chemotherapy for cancer</b> .....	<b>96</b>
TDM of 5-FU.....	96
TDM of imitانب .....	97
TDM of Methotrexate .....	97
TDM of paclitaxel .....	98
<b>Drugs used for treatment of Alzheimer disease</b> .....	<b>98</b>
Donepezil.....	98
Galantamine.....	98
Memantine .....	99
<b>Drugs used for treatment of Parkinson disease</b> .....	<b>99</b>
Monitoring of levodopa and carbidopa therapy.....	100
Catechol-O-methyltransferase inhibitors .....	100
<b>Drugs for treatment of attention-deficit hyperactivity disorder</b> .....	<b>100</b>
Atomoxetine.....	100
Methylphenidate .....	101
<b>Hypnotic-sedative drugs</b> .....	<b>101</b>
Benzodiazepines .....	102
Propofol.....	102
<b>Immunosuppressive drugs</b> .....	<b>103</b>
Immunosuppressants used for the treatment of various diseases .....	103
<i>Azathioprine</i> .....	103
<i>Hydroxychloroquine for patients with systemic lupus erythematosus</i> .....	103
<i>Methotrexate for rheumatoid arthritis</i> .....	103
<i>Mycophenolic acid for the treatment of lupus nephritis</i> .....	104
Immunosuppressants used for prevention of organ rejection in transplantation .....	104
TDM of Tacrolimus in transplantation .....	104
TDM of cyclosporine A in transplantation .....	105
Monitoring of immunosuppression with mycophenolate mofetil .....	105
<b>Steroids</b> .....	<b>106</b>
Prednisone .....	106
<b>Miscellaneous drugs</b> .....	<b>107</b>
Nimodipine.....	107
Sildenafil .....	107
<b>6. Monitoring of Biological Therapies</b> .....	<b>108</b>
<b>Introduction</b> .....	<b>108</b>
<b>Cell therapy</b> .....	<b>108</b>
In vivo tracking of cells.....	108
<i>Molecular imaging for tracking cells</i> .....	108
<i>MRI technologies for tracking cells</i> .....	109
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i> .....	110
<i>Visualization of gene expression in vivo by MRI</i> .....	110
<b>Gene therapy</b> .....	<b>111</b>
<b>Application of molecular diagnostic methods in gene therapy</b> .....	<b>111</b>
Use of PCR to study biodistribution of gene therapy vector.....	111
PCR for verification of the transcription of DNA .....	112
In situ PCR for direct quantification of gene transfer into cells .....	112
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	112
Confirmation of viral vector integration .....	112
Monitoring of gene expression .....	112
<i>Monitoring of gene expression by green fluorescent protein</i> .....	113
<i>Monitoring in vivo gene expression by molecular imaging</i> .....	113
<b>Monoclonal antibodies</b> .....	<b>114</b>
Natalizumab .....	114

<b>7. Monitoring of Drug Abuse .....</b>	<b>116</b>
<b>Introduction .....</b>	<b>116</b>
<b>Tests used for detection of drug abuse .....</b>	<b>117</b>
Forensic applications of detection of illicit drugs in fingerprints by MALDI MS .....	117
MS for doping control .....	118
Randox assays for DoA .....	118
Drugs of Abuse Array V .....	118
Urine drug testing .....	119
<b>TDM of drugs for treatment of substance abuse-related disorders .....</b>	<b>119</b>
<b>Drug testing to monitor treatment of drug abuse .....</b>	<b>119</b>
Minimum requirement for drug testing in patients .....	120
<b>Analgesic abuse .....</b>	<b>120</b>
Fentanyl abuse .....	120
<b>B-blockers as doping agents .....</b>	<b>121</b>
Detection of $\beta$ -blockers in urine .....	121
<b>Chronic alcohol abuse .....</b>	<b>121</b>
<b>Cocaine .....</b>	<b>122</b>
CEDIA for cocaine in human serum .....	122
Detection of cocaine molecules by nanoparticle-labeled aptasensors .....	122
Infrared spectroscopy for detection of cocaine in saliva .....	122
<b>Marijuana .....</b>	<b>123</b>
Use of marijuana and synthetic cannabinoids .....	123
Detection of cannabinoids .....	124
<i>ELISA for detection of synthetic cannabinoids .....</i>	<i>124</i>
<b>Drug abuse for performance enhancement in sports .....</b>	<b>124</b>
Historical aspects of drug abuse in sports .....	124
Drugs used by athletes for performance enhancement .....	125
Techniques used for detection of drug abuse by athletes .....	127
<i>Mass spectrometry for detection of peptide hormones .....</i>	<i>127</i>
<i>miRNAs for the detection of erythropoiesis-stimulating agents .....</i>	<i>127</i>
<i>Detection of anabolic steroids .....</i>	<i>127</i>
Body fluids and tissues used for detection of drug abuse in sports .....	128
<i>Urine drug testing .....</i>	<i>128</i>
<i>Spray (sweat) drug test kits .....</i>	<i>128</i>
<i>Hair drug testing .....</i>	<i>128</i>
Gene doping in sports .....	128
<i>Gene transfer methods used for enhancing physical performance .....</i>	<i>129</i>
<i>Misuse of cell therapy in sport .....</i>	<i>130</i>
<i>Challenges of detecting genetic manipulations in athletes .....</i>	<i>131</i>
Drug abuse testing in race horses .....	131
<b>Limitations and future .....</b>	<b>132</b>
Role of pharmaceutical industry in anti-doping testing .....	133
<b>8. Markets for TDM .....</b>	<b>134</b>
<b>Introduction .....</b>	<b>134</b>
<b>Methods for market estimation and future forecasts .....</b>	<b>134</b>
Global markets for TDM tests .....	134
Global markets for TDM according to technologies .....	135
Global TDM markets according to drug categories .....	135
<i>Agents used for treatment of Alzheimer disease .....</i>	<i>136</i>
<i>Analgesics .....</i>	<i>136</i>
<i>Anticancer agents .....</i>	<i>136</i>
<i>Anticoagulants .....</i>	<i>136</i>
<i>Antidepressants .....</i>	<i>137</i>
<i>Antiepileptics .....</i>	<i>137</i>
<i>Antimicrobials .....</i>	<i>137</i>
<i>Antipsychotics .....</i>	<i>137</i>
<i>Biological therapies .....</i>	<i>137</i>
<i>Bronchodilators .....</i>	<i>138</i>
<i>Cardiovascular drugs .....</i>	<i>138</i>
<i>Corticosteroids/antihistaminics/antiinflammatory agents .....</i>	<i>138</i>
<i>Hypnotic-sedatives .....</i>	<i>138</i>
<i>Immunosuppressants .....</i>	<i>138</i>
<i>Parkinson disease drugs .....</i>	<i>138</i>
Breakdown of global markets according to point of application of tests .....	138
Markets for TDM and DoA testing equipment .....	139
Geographical distribution of markets for TDM tests .....	139
Drivers for growth of TDM markets .....	140
Markets for DoA testing .....	141
<b>Unmet needs in TDM .....</b>	<b>141</b>
Cost-benefit studies .....	142

Simplifying assays and reducing time and cost .....	143
<b>Strategies for developing markets .....</b>	<b>143</b>
Physician education .....	144
Supporting research on TDM .....	144
Biomarker patents for drug monitoring .....	144
<b>9. Companies .....</b>	<b>146</b>
<b>Profiles of companies.....</b>	<b>146</b>
<b>Collaborations.....</b>	<b>193</b>
<b>10. References.....</b>	<b>194</b>

### Tables

Table 1-1: Historical landmarks in the development of therapeutic drug monitoring .....	12
Table 4-1: Psychotropic drugs requiring TDM .....	68
Table 5-1: Drugs requiring TDM.....	72
Table 5-2: Indications and therapeutic ranges of various AEDs .....	77
Table 6-1: Molecular imaging methods for tracking cells in vivo .....	109
Table 6-2: Applications of molecular diagnostics in gene therapy .....	111
Table 7-1: Commonly tested drugs of abuse and recreational drugs .....	116
Table 7-2: Testing and confirmation cutoff concentrations/detection times for DoA .....	120
Table 7-3: Historical landmarks of drug abuse in sports.....	125
Table 7-4: Drugs used by athletes for performance enhancement .....	125
Table 7-5: Genes that may be used for performance enhancement .....	129
Table 8-1: Global markets for TDM according to technologies from 2017-2027 .....	135
Table 8-2: Global markets for TDM according to tests in drug categories 2017-2027 .....	135
Table 8-3: Global markets for TDM according to point of application 2017-2027 .....	139
Table 8-4: Markets for TDM and DoA testing equipment 2017-2027 .....	139
Table 8-5: Geographical distribution of markets for TDM tests 2017-2027 .....	140
Table 8-6: Drivers for growth of TDM markets.....	140
Table 8-7: Global markets for DoA testing 2016-2026 .....	141
Table 9-1: Major players in therapeutic drug monitoring.....	146
Table 9-2: Drugs for which monitoring and detection tests are provided by LabCorp .....	167
Table 9-3: Collaborations of companies involved in TDM.....	193

### Figures

Figure 1-1: Therapeutic window of a drug .....	15
Figure 1-2: Therapeutic range of a drug .....	15
Figure 1-3: Flow chart of TDM .....	17
Figure 1-4: Interrelationships of TDM .....	17
Figure 2-1: Separation of structurally similar drug molecules by HPLC.....	24
Figure 2-2: Determination of the identity of a target substance by mass spectrometry .....	24
Figure 2-3: Basic principle of a biosensor.....	29
Figure 8-1: Unmet needs in TDM .....	142
Figure 8-2: Metabolism of azathioprine and biomarkers for TDM .....	145